

“Molekylær klassifikation af brystkræft”

DBCG

**Repræsentantskabsmøde, 23.01.17,
Rigshospitalet.**

- Maria Rossing, MD, PhD
- Center for Genomic Medicine, GM4113, Rigshospitalet, Copenhagen University Hospital, Denmark

Genomisk Medicin, RH





- sikre effektiv og præcis diagnostik og facilitere behandlingsbeslutninger
- skal være på forkant med molekylærgenetiske analyser
- sikre at de kliniske afdelinger har adgang til high-throughput teknologier

Genomisk Medicin, RH

- Diagnostisk enhed
- Forsknings enhed
- NGS Core Facilitet
- Microarray Core Facilitet

- Arvelige sygdomme
(cancer, endokrinologi,
hæmatologi)
- Cancer diagnostik
- Målrettet cancerbehandling
- Mikrobio- og virologi

Microarray Core Facilitet



Brystkræft; Molekylær klassifikation

- Transkriptionelle tumorprofiler har muliggjort klassificering af brystkræft i distinkte og biologisk forskellige subklasser
- Korrelerer med kliniske karakteristika og prognose

- *“However, in clinical practice, the key question is not the separation of the molecularly defined intrinsic subtypes, but the discrimination between patients who will or will not benefit from particular therapies”*

Subtypeklassifikationsmodel på RH

Oncogene (2012) 31, 1196–1206

© 2012 Macmillan Publishers Limited. All rights reserved 0950-9232/12

www.nature.com/fnc

ONCOGENOMICS


A refined molecular taxonomy of breast

M Guedj^{1,15}, L Marisa^{1,15}, A de Reynies^{1,15}, B Orsetti^{1,15},
F Lerebours⁶, P Finetti⁷, M Longy⁵, P Bertheau⁸, I
JP Feugeas^{10,11,12}, I Bièche⁶, J Lehmann-Che^{10,11,12},
H de Thé^{10,11,12,15} and C Theillet^{2,13,14,15}


¹Ligue Nationale Contre le Cancer, Cartes d'Identité des Tumeurs pour la
Cancérologie de Montpellier, Montpellier, France; ²CRLC Val d'Aurelle
Pathology, CRLC Val d'Aurelle Paul Lamarque, Montpellier, France
Université Victor Segalen Bordeaux-2, Bordeaux, France; ⁶Oncogenet
René Huguenin, St Cloud, France; ⁷Department of Molecular Oncology
Institut Paoli Calmette, Marseille, France; ⁸Hopital St Louis APHP,
Paris, France; ⁹Fédération Nationale des Centres de Lutte Contre le Cancer
Saint-Louis APHP, Paris, France; ¹¹INSERM/CNRS UMR 944/7212, Paris
Paris-7 Denis Diderot, Paris, France; ¹³INSERM U896, CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France and ¹⁴Université
Montpellier 1, Montpellier, France

- 256 gener
- 6 subklasser
- Genomisk data (incl.CNV)
- Korrelerer med kliniske karakteristika og prognose
- Robust (>3000 pt.)
- Affymetrix platform (open)
- "In house"


a




b




c



d








Figure 1: PCA on CIT data used to classify dataset & sample (black).


Classification	Mixed	Confidence
mApo	-	CORE

Possible confidences are: CORE, MIXED, and OUTLIER. If the confidence is MIXED, Classification lists the second of the two overlapping clusters under Mixed. In the case of an OUTLIER, the nearest cluster is listed under Classification.

Expression profiles

Her2	ERBB2	positive
Estrogen receptor	ESR1	negative
Progesterone receptor	PGR	negative

Proliferation Index(PI) score (tumor PI >5.5): 6.68



Classification	Mixed	Confidence
mApo	-	CORE

Her2	ERBB2	positive
Estrogen receptor	ESR1	negative
Progesterone receptor	PGR	negative

Proliferation Index(PI) score (tumor PI >5.5): 6.68